REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
21 hedge funds and large institutions have $5.76M invested in REVIVA PHARMA HLDGS INC in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 6 closing their positions.
55% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $821K
4% more capital invested
Capital invested by funds: $5.54M → $5.76M (+$222K)
0.02% more ownership
Funds ownership: 0.32% → 0.34% (+0.02%)
9% less funds holding
Funds holding: 23 → 21 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$469K |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
+$406K |
| 3 |
Millennium Management
New York
|
+$168K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$127K |
| 5 |
Belvedere Trading
Chicago,
Illinois
|
+$27.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$249K |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$164K |
| 3 |
Two Sigma Investments
New York
|
-$134K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$80.5K |
| 5 |
Goldman Sachs
New York
|
-$74.1K |
RVPH Hedge Fund Activity: Q1 2023 in Review
21 of the 6,278 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q1 2023, worth a combined $5.76M — up 4% from $5.54M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RVPH and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $469K. The largest seller was XTX Topco, exiting entirely with an estimated $249K sold.
- 21 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q1 2023, down from 23 in Q4 2022.
- Funds reported $5.76M of REVIVA PHARMA HLDGS INC stock for Q1 2023, up 4% quarter-over-quarter.
- 4 funds opened new REVIVA PHARMA HLDGS INC positions in Q1 2023 and 6 closed out, a net change of -2 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q1 2023 was Vanguard Group, an estimated $469K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q1 2023 was XTX Topco, an estimated $249K sold.
Based on aggregated 13F filings for Q1 2023.